The impact of perampanel and targeting AMPA transmission on anti-seizure drug discovery-Reference-Cited by-同舟云学术

The impact of perampanel and targeting AMPA transmission on anti-seizure drug discovery

Published:2019-01-11 Issue:3 Volume:14 Page:195-197
ISSN:1746-0441
Container-title:Expert Opinion on Drug Discovery
language:en
Short-container-title:Expert Opinion on Drug Discovery

Author:

Lattanzi Simona¹,Striano Pasquale²^ORCID

Affiliation:

1. Department of Experimental and Clinical Medicine, Neurological Clinic, Marche Polytechnic University, Ancona, Italy

2. Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, “G. Gaslini” Institute, Genova, Italy

Funder

funded

Publisher

Informa UK Limited

Subject

Drug Discovery

Link

https://www.tandfonline.com/doi/pdf/10.1080/17460441.2019.1566318

Reference15 articles.

1. Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis

2. Remission of epilepsy: results from the National General Practice Study of Epilepsy

3. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis

4. AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives

5. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness, safety and tolerability of perampanel by age group when used to treat people with focal and generalized epilepsy in clinical practice: The PERMIT Extension study;Epilepsy & Behavior;2023-10

2. Efficacy and safety of perampanel monotherapy in Chinese patients with focal‐onset seizures: A single‐center, prospective, real‐world observational study;Epilepsia Open;2023-09-25

3. Long-term efficacy and safety of adjunctive perampanel in pediatric patients aged 4–19 years with epilepsy: a real-world study;Scientific Reports;2023-09-01

4. Perampanel for the treatment of people with idiopathic generalized epilepsy in clinical practice;Epilepsia;2023-06-04

5. Long-term efficacy and safety of adjunctive perampanel in pediatric patients aged 4 – 19 years with drug-resistant epilepsy: a real-world study;2023-05-15